Marinus Pharmaceuticals (MRNS) Investor & Analyst 2024 summary

Strategic vision and future plans

• Expanding ganaxolone (ZTALMY®) from CDKL5 deficiency disorder (CDD) into tuberous sclerosis complex (TSC), with a U.S. NDA filing targeted for April 2025 and leveraging a proven commercial model for rapid market entry and growth.

• Global expansion is underway, with launches in Europe and China imminent, and partnerships in MENA and other regions to drive ex-U.S. milestones and royalty revenue.

• A new U.S. patent extends ganaxolone protection to 2043, supporting further development in other developmental and epileptic encephalopathies (DEEs) and Lennox-Gastaut syndrome (LGS), with new clinical trials set to begin in the second half of 2025.

• Development of a second-generation ganaxolone prodrug aims to improve dosing, efficacy, and side effect profile, with IND submission targeted for late 2025.

• The company aims for total profitability within 18 months of the U.S. TSC launch, driven by efficient spend, scalable operations, and leveraging established commercial infrastructure.

Clinical development and data insights

• Phase 3 TrustTSC trial for TSC is complete, with top-line data expected in early Q4 2024; the study is powered to detect a 25% treatment difference and includes patients on standard-of-care therapies.

• Revised titration schedule, informed by Phase 2 and PK data, has reduced somnolence-related adverse events and improved patient retention and efficacy.

• Long-term extension data in TSC show sustained seizure reduction (median 56% at two years, 87% at 22-24 months) and favorable safety profile.

• Ganaxolone demonstrates broad-spectrum anti-seizure activity, minimal drug-drug interactions, and no need for routine lab monitoring, differentiating it from competitors.

• Real-world and clinical experience indicate that effective titration and patient support are key to maximizing efficacy and tolerability.

Commercial strategy and market opportunity

• ZTALMY® achieved 87% revenue growth in the past year, with 2024 full-year guidance of $33–$35 million and over 200 patients on active therapy.

• TSC market is 6-7 times larger than CDD, with ~12,700 refractory patients identified as the initial target; faster uptake is expected due to easier diagnosis and established payer relationships.

• Commercial investment for TSC launch is incremental, leveraging existing infrastructure; projected annualized revenue run rate for TSC is $170M–$220M within 18 months, with total company profitability anticipated in the same timeframe.

• Global partnerships are expected to yield over $25M in near-term milestones and $300M+ in potential revenue-driven milestones, with double-digit royalties.

• Combined commercial investment for CDD and TSC is expected to remain under $50M, with SG&A expenses projected below $100M and a cash runway into Q2 2025.